Danisco (Copenhagen) is strengthening its position in the vitamin K2 market through a new partnership with synthetic vitamin k2 supplier Kappa Bioscience AS (Oslo, Norway).
Danisco (Copenhagen) is strengthening its position in the vitamin K2 market through a new partnership with synthetic vitamin k2 supplier Kappa Bioscience AS (Oslo, Norway).
Rapidly increasing science and market awareness is making vitamin K2 a popular product for heart health and bone health.
Danisco offers a natural form of vitamin K2 MK-7 in its ActivK ingredient; meanwhile, the company says that Kappa Bioscience is established as the first company to have developed a synthetic form of K2 MK-7.
“This new agreement between Danisco and Kappa Bioscience will enable the expansion of Vitamin K2 into broad market segments,” says Peter Wisler, Danisco Health & Nutrition director of business development. “Not only will this aid the availability of a broader format of end products, [sic] it will also increase awareness and education amongst consumers, thus establishing this vitamin alongside many other highly functional and necessary vitamins.”
Glanbia Nutritionals announces launch of high potency collagen tripeptide ingredient
June 4th 2024According to the company, Collamet is absorbed four times faster and has 10 times the efficacy of traditional collagen peptides. The ingredient will initially be offered in the North American market.